A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production Durvanei Augusto MariaJean Gabriel de SouzaAna Marisa Chudzinski-Tavassi PRECLINICAL STUDIES Open access 14 September 2012 Pages: 493 - 505
A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [18F]fluorothymidine-positron emission tomography Seung Jin LeeEun Jung KimSang-We Kim PRECLINICAL STUDIES 18 September 2012 Pages: 506 - 515
Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab Ch. GialeliA. D. TheocharisN. K. Karamanos PRECLINICAL STUDIES 06 September 2012 Pages: 516 - 524
Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells Amna AliTatyana S. SidorovaDiane F. Matesic PRECLINICAL STUDIES 10 October 2012 Pages: 525 - 534
The novel antiangiogenic VJ115 inhibits the NADH oxidase ENOX1 and cytoskeleton-remodeling proteins Amudhan VenkateswaranDavid B. FriedmanKonjeti R. Sekhar PRECLINICAL STUDIES 09 October 2012 Pages: 535 - 544
Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways Patrick T. GroganKristina D. SlederMark S. Cohen PRECLINICAL STUDIES 06 November 2012 Pages: 545 - 557
EGFR and HER2 inhibition in pancreatic cancer Naomi WalshSusan KennedyNorma O’Donovan PRECLINICAL STUDIES 18 October 2012 Pages: 558 - 566
Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines Brigette B. Y. MaVivian W. Y. LuiAnthony T. C. Chan PRECLINICAL STUDIES 11 November 2012 Pages: 567 - 575
Characterization of a membrane-active anti-tumor agent, UA8967 Robert T. DorrBetty K. SamulitisDaniel D. Von Hoff PRECLINICAL STUDIES 23 November 2012 Pages: 576 - 586
Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system Jenny FelthKarolina Lesiak-MieczkowskaLinda Rickardson PRECLINICAL STUDIES 20 November 2012 Pages: 587 - 598
A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer Yoshikazu HasegawaIsamu OkamotoKazuhiko Nakagawa PHASE I STUDIES 24 May 2012 Pages: 599 - 604
Metabolism of patupilone in patients with advanced solid tumor malignancies Kevin R. KellyMarkus ZollingerMonica Mita PHASE I STUDIES 18 July 2012 Pages: 605 - 615
A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: Crossover comparisons with intravenous paclitaxel Yong Sang HongKyu-pyo KimTae Won Kim PHASE I STUDIES 14 June 2012 Pages: 616 - 622
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors Christophe MassardJane MargettsRuth Plummer PHASE I STUDIES 12 June 2012 Pages: 623 - 630
A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers A. F. BakerK. N. AdabT. Dragovich PHASE I STUDIES 19 June 2012 Pages: 631 - 641
Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas Tanja TrarbachMarta PrzyborekUdo Vanhoefer PHASE I STUDIES 05 July 2012 Pages: 642 - 652
Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics Nwabundo NwankwoZhe ZhangMichael A. Carducci PHASE I STUDIES Open access 06 July 2012 Pages: 653 - 660
A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer J. T. HartmannC. KollmannsbergerC. Bokemeyer PHASE I STUDIES 26 July 2012 Pages: 661 - 668
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer Gary HudesScott T. TagawaMario Eisenberger PHASE I STUDIES 25 July 2012 Pages: 669 - 676
Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study Hajime AsahinaHiroshi NokiharaTomohide Tamura PHASE I STUDIES 28 July 2012 Pages: 677 - 684
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors Amir MortazaviYonghua LingTanios Bekaii-Saab PHASE I STUDIES 31 July 2012 Pages: 685 - 695
REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors Don G. MorrisXiaolan FengBrad Thompson PHASE I STUDIES 12 August 2012 Pages: 696 - 706
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma Andrea Wang-GillamStacey Plambeck-SuessWilliams G. Hawkins PHASE I STUDIES 04 August 2012 Pages: 707 - 713
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors Michael S. GordonLee S. RosenGlen J. Weiss PHASE I STUDIES 29 September 2012 Pages: 714 - 723
Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction J. P. DelordA. RavaudF. Saliba PHASE I STUDIES 21 September 2012 Pages: 724 - 733
Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors A. H. AwadaH. DumezP. Schöffski PHASE I STUDIES Open access 17 November 2012 Pages: 734 - 741
A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors Geoffrey I. ShapiroStewart McCallumPatricia LoRusso PHASE I STUDIES 06 October 2012 Pages: 742 - 750
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors Maja J. A. de JongePaul HambergHerbert I. Hurwitz PHASE I STUDIES 06 October 2012 Pages: 751 - 759
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer Kenneth J. PientaJean-Pascal MachielsJohann S. de Bono PHASE II STUDIES 21 August 2012 Pages: 760 - 768
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma Tara C. GangadharJoseph I. ClarkThomas F. Gajewski PHASE II STUDIES 15 November 2012 Pages: 769 - 773
Determinants of patient screen failures in Phase 1 clinical trials Alexandra MckaneChao SimaGlen J. Weiss SHORT REPORT 08 November 2012 Pages: 774 - 779
Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1 Erika RimondiPaola SecchieroGiorgio Zauli SHORT REPORT 16 November 2012 Pages: 780 - 786
The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis Alyssa FischerShenhong WuMario E. Lacouture REVIEW 24 January 2013 Pages: 787 - 797
Erratum to: Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study Hajime AsahinaHiroshi NokiharaTomohide Tamura Erratum 05 September 2012 Pages: 798 - 798
Erratum to: Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors Christophe MassardJane MargettsRuth Plummer Erratum 21 April 2013 Pages: 799 - 799
Erratum to: Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA Serena MarchettiDick PluimJan H. M. Schellens Erratum 11 April 2013 Pages: 800 - 800
